PT3334431T - 5-bromo-2,6-di-(1h-pirazol-l-il)pirimidin-4-amina para uso no tratamento do cancro - Google Patents

5-bromo-2,6-di-(1h-pirazol-l-il)pirimidin-4-amina para uso no tratamento do cancro

Info

Publication number
PT3334431T
PT3334431T PT167663848T PT16766384T PT3334431T PT 3334431 T PT3334431 T PT 3334431T PT 167663848 T PT167663848 T PT 167663848T PT 16766384 T PT16766384 T PT 16766384T PT 3334431 T PT3334431 T PT 3334431T
Authority
PT
Portugal
Prior art keywords
pyrazol
pyrimidin
bromo
cancer
amine
Prior art date
Application number
PT167663848T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Novartis Ag
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Palobiofarma Sl filed Critical Novartis Ag
Publication of PT3334431T publication Critical patent/PT3334431T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT167663848T 2015-08-11 2016-08-10 5-bromo-2,6-di-(1h-pirazol-l-il)pirimidin-4-amina para uso no tratamento do cancro PT3334431T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382425 2015-08-11
US201662335984P 2016-05-13 2016-05-13

Publications (1)

Publication Number Publication Date
PT3334431T true PT3334431T (pt) 2020-01-06

Family

ID=65563017

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167663848T PT3334431T (pt) 2015-08-11 2016-08-10 5-bromo-2,6-di-(1h-pirazol-l-il)pirimidin-4-amina para uso no tratamento do cancro

Country Status (13)

Country Link
JP (1) JP6964113B2 (ja)
KR (1) KR102226100B1 (ja)
CL (1) CL2018000349A1 (ja)
DK (1) DK3334431T3 (ja)
ES (1) ES2761910T3 (ja)
HK (1) HK1249409B (ja)
HR (1) HRP20192192T1 (ja)
HU (1) HUE046646T2 (ja)
IL (1) IL257350A (ja)
LT (1) LT3334431T (ja)
PT (1) PT3334431T (ja)
RU (1) RU2745560C2 (ja)
ZA (1) ZA201800792B (ja)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.

Also Published As

Publication number Publication date
JP2019218346A (ja) 2019-12-26
RU2745560C2 (ru) 2021-03-29
LT3334431T (lt) 2019-12-27
RU2018108050A (ru) 2019-09-13
ES2761910T3 (es) 2020-05-21
KR20200057790A (ko) 2020-05-26
JP6964113B2 (ja) 2021-11-10
ZA201800792B (en) 2019-06-26
CL2018000349A1 (es) 2018-09-07
IL257350A (en) 2018-03-29
HUE046646T2 (hu) 2020-03-30
DK3334431T3 (da) 2020-01-02
RU2018108050A3 (ja) 2020-02-17
HRP20192192T1 (hr) 2020-03-06
HK1249409B (zh) 2020-05-08
KR102226100B1 (ko) 2021-03-10

Similar Documents

Publication Publication Date Title
SG10202111808WA (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
HK1256283A1 (zh) 治療癌症有用的二氫咪唑並吡嗪酮衍生物
IL263802A (en) Combinations of cancer treatments
IL251905B (en) Epilimod for use in the treatment of kidney cancer
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
IL251903A0 (en) Epilimod for use in the treatment of colon cancer
EP3733184C0 (en) PYRROLOPYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
IL262143A (en) Improvements in cancer treatment
EP3337784A4 (en) USE OF UREIDOMUSTIN (BO-1055) IN THE TREATMENT OF CANCER
HK1251794A1 (zh) 癌症治療
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
EP3440052C0 (en) COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
IL269121A (en) Usl-311 for use in the treatment of cancer
IL257350A (en) 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
GB201522433D0 (en) Cancer treatment
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
GB2553684B (en) Ethynylxanthines, preparation and use for cancer treatment